Dr. Shakti Singh from the Division of Infectious Diseases has been awarded the prestigious five-year K01 Grant for their innovative research on the deadly fungal pathogen Candida auris. This five-year grant, provided by the National Institutes of Health (NIH), supports Dr. Singh’s cutting-edge work, which aims to unravel the complex mechanisms of C.
-
- We’re thrilled to announce that the California Institute for Regenerative Medicine (CIRM) has awarded a Shared Resources Laboratory: “the Stem Cell-based Partnership Resource for Investigating Human Diseases and Training (SPRINT)” to Dr. Denise Al Alam, PhD at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI). Other TLI investigators involved in this award include Dr. Michelina Iacovino, PhD, Dr.
TLI Welcomes a New Incoming Board Member and Thanks Two Outgoing Members
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI) announced updates to its Board of Directors. TLI welcomes one new distinguished member and thanks the two outgoing members for their invaluable contributions.
The award recognizes TLI’s WIC Program for Outstanding Achievement
in Supporting and Promoting Breastfeeding Among It Participants
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI) is pleased to announce that its WIC Program has received the U.S. Department of Agriculture’s Food and Nutrition Service (FNS) 2024 WIC Breastfeeding Gold Award of Excellence.
The study found that anakinra is safe and effective in improving neurobehavioral and functional outcomes for patients with Sanfilippo syndrome
Investigator(s):
Lynda Polgreen, MD, MS
The groundbreaking study was led by Lynda Polgreen, MD, MS, Investigator at The Lundquist Institute for Biomedical Innovation (TLI) and Associate Professor of Pediatrics at the David Geffen School of Medicine at UCLA, focused on using anakinra, a recombinant interleukin-1 receptor antagonist, on addressing the neuroinflammation component of Sanfilippo Syndrome.
A groundbreaking study published in the Journal of the American College of Emergency Physicians Open demonstrates that adhering to national pediatric care guidelines in emergency departments (EDs) saves children’s lives and is cost-effective, ranging from $4 to $48 per patient. This pivotal research by TLI’s Dr. Marianne Gausche-Hill offers compelling evidence about the financial feasibility of being "pediatric ready."
Investigator(s):
Marianne Gausche-Hill, MD, FACEP, FAAP, FAEMS
Becoming highly pediatric-ready could decrease child mortality rates by up to 76%
Marking a special milestone for medical research, Mary Burns, a 94-year-old trailblazer in the battle against COPD, made her return to The Lundquist Institute
Investigator(s):
Richard Casaburi, PhD, MD
Marking a special milestone for medical research, Mary Burns, a 94-year-old trailblazer in the battle against chronic obstructive pulmonary disease (COPD), made her return to The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI). Fifteen years ago, Burns was the first to join the COPDGene study — a cutting-edge investigation seeking to unravel the complexities of COPD. As she walked through the doors of the Respiratory Research Center, it was more than just a routine check-up; it marked the inauguration of "Phase 4" of this pivotal study.
The proposed sensor has the potential to not only revolutionize COPD management but also to impact healthcare by incorporating wearable electronics into chronic disease management
Investigator(s):
Harry Rossiter, PhD
The U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded The Lundquist Institute (TLI) a four-year grant totaling $2,623,234. The research project is led by Dr. Harry Rossiter, an investigator at TLI and Professor at the David Geffen School of Medicine at UCLA. The project aims to develop wearable multiplex biosensors to monitor exacerbation risk in chronic obstructive pulmonary disease (COPD).
TLI Welcomes Four Incoming Board Members and Thanks Four Outgoing Members
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI) has announced changes to its Board of Directors. The organization welcomes four distinguished incoming members and thanks the outgoing members for their invaluable contributions.
This study is poised to generate crucial new Down Syndrome cell lines to study genetic defects specific to Down Syndrome.
Investigator(s):
Denise Al Alam, PhD
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI) has announced that The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded $1.5 million to TLI Investigator Denise Al Alam, PhD, to support research that aims to understand lung disease in individuals with Trisomy 21 (also known as Down Syndrome). Although Trisomy 21 impacts multiple organ systems, respiratory complications are a significant cause of death in children and adults with this genetic condition.